Relation between duration of smoking cessation and bronchial inflammation in COPD

Lapperre, I. S.; Postma, D. S.; Gosman, M. M. E.; Snoeck-Stroband, J. B.; Ten Hacken, N. H. T.; Hiemstra, P. S.; Timens, W.; Sterk, P. J.; Mauad, T.
February 2006
Thorax;Feb2006, Vol. 61 Issue 2, p115
Academic Journal
Background: Chronic obstructive pulmonary disease (COPD) is associated with airway inflammation. Although smoking cessation improves symptoms and the decline in lung Function in COPD, it is unknown whether bronchial inflammation in patients with established COPD varies with the duration of smoking cessation. Methods: 114 patients (99 men) with COPD of mean (SD) age 62 (8) years, a median (IQR) smoking history of 42 (31-55) pack years, no inhaled or oral corticosteroids, all current or ex-smokers (n = 42, quit >1 month, median cessation duration 3.5 years), post-bronchodilator FEV1 63 (9)% predicted, and FEV1/IVC 48 (9)% were studied cross sectionally. The numbers of subepithelial T lymphocytes (CD3, CD4, CD8), neutrophils, macrophages, eosinophils, mast cells, and plasma cells were measured in bronchial biopsy specimens (median (IQR)/0.1 mm²) using Fully automated image analysis. Results: Ex-smokers with COPD had higher CD3+, CD4+, and plasma cell numbers than current smokers with COPD (149 (88-225) v 108 (61-1 64), p=0.036 58 (32-90) v 40 (25-66), p=0.023; and 9.0 (5.5-20) v 7.5 (3.1-14), p=0.044, respectively), but no difference in other inflammatory cells. Short term ex-smokers (⩾3.5 years) had higher CD4+ and CD8+ cell numbers than current smokers (p = 0.017, p=0.023 respectively). Conversely, long term ex-smokers (quit 13.5 years) had lower CD8+ cell numbers than short term ex-smokers (p = 0.009), lower CD8/CD3 ratios than both current smokers and short-term ex-smokers (p=0.012, p=0.003 respectively), and higher plasma cell numbers than current smokers (p=0.003). Conclusions: With longer duration of smoking cessation, CD8 cell numbers decrease and plasma cell numbers increase. This indicates that bronchial T lymphocyte and plasma cell counts, but not other inflammatory cells, are related to duration of smoking cessation in patients with COPD.


Related Articles

  • Review: Inhaled corticosteroids slow the progression of airflow limitation in COPD.  // ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p57 

    In patients with chronic obstructive pulmonary disease (COPD), inhaled corticosteroids reduce the progression of airflow limitation. Inhaled corticosteroids (ICS) slow the progression of airflow limitation in COPD Studies were selected if they were full reports of randomized controlled trials of...

  • Impact of Smoking on Asthma Therapy: A Critical Review of Clinical Evidence. Livingston, Eric; Thomson, Neil C.; Chalmers, George W. // Drugs;2005, Vol. 65 Issue 11, p1521 

    Airway inflammation is central to the pathophysiology of asthma, with treatment directed towards modification of this inflammation and its consequences. The relationship between cigarette smoking and airway inflammation is also well described, but relatively little data are available on the...

  • Is there more than one inflammatory phenotype is asthma? O'Donnell, R. A.; Frew, A. J. // Thorax;Jul2002, Vol. 57 Issue 7, p566 

    The article discusses whether there is more than one inflammatory phenotype in asthma. But there are some problems in asthma investigations. Most asthmatic patients recruited to these studies either had severe disease or were on some form of corticosteroid therapy, raising concerns about...

  • Non-eosinophilic asthma and the innate immune response. Pavord, Ian D. // Thorax;Mar2007, Vol. 62 Issue 3, p193 

    The article looks at the reasons for the renewed interest in the investigation of non-eosinophilic asthma. Some studies have suggested that non-eosinophilic asthma is associated with a poor short-term immune response to inhaled corticosteroid therapy. There is also a possibility that a different...

  • Biopharmaceutical Therapeutics for Asthma Remodeling. Das, A. M.; Griswold, D. E.; Torphy, T. J.; Li, L. // Current Pharmaceutical Design;Sep2006, Vol. 12 Issue 25, p3233 

    Current asthma therapy is aimed at controlling disease symptoms. A subset of asthma patients remains symptomatic despite optimal therapy indicating that an unmet medical need exists for these patients. Innovative therapeutics are needed to treat the unmet need in asthma and biopharmaceutical...

  • Asthma: clinical assessment.  // Thorax;Dec2004 Supplement, Vol. 59, p50 

    The article presents some papers related to clinical assessment of asthma. There is currently great interest in developing non-invasive measures of airway inflammation in asthma. Proposed markers of airway inflammation and or oxidative stress in asthma include the exhaled gases, nitric oxide...

  • Mechanisms and Therapeutic Implications of Asthma Circadian Rhythm. Vianna, Elcio O. // Current Respiratory Medicine Reviews;2005, Vol. 1 Issue 2, p171 

    Nocturnal worsening of asthma is very common and employed in clinical practice as a marker of asthma severity. The fall in overnight lung function can reach 50%. Several mechanisms contribute to this circadian (24 h) variation. Cortisol, steroid responsiveness, vagal tone, leukotriene, airway...

  • Beclazone Easi-Breathe.  // Royal Society of Medicine: Medicines;2002, p100 

    The article presents information on beclazone easi-breathe, a proprietary, prescription-only preparation of the corticosteroid beclometasone dipropionate. It can be used to prevent asthma attacks and is available in forms for aerosol inhalation with breath-actuated units.

  • Asthma meds: Getting to the right answer. Corjulo, Michael // Contemporary Pediatrics;Jul2007, Vol. 24 Issue 7, p87 

    The article offers tips about asthma medications from a medical professional. He states that when asking patients about their adherence to their medication regime, patients' answers can be too vague to be of any use. He offers that when he talks to an older child about the use of controller...


Read the Article


Sign out of this library

Other Topics